How Long Does Psilocybin Last for Depression? The Evidence

Psilocybin & Depression

4.5-year follow-up

60-80% of participants who received psilocybin maintained significant improvements in depression and anxiety at a 4.5-year follow-up — the longest duration data currently available from any psilocybin trial.

Agin-Liebes et al., Journal of Psychopharmacology, 2020

71%

response rate at 4 weeks in the Hopkins MDD trial (Davis et al., JAMA Psychiatry, 2021)

54%

remission rate at 4 weeks in the same trial, maintained in the majority at 12 months

~37%

average MADRS reduction with a single 25mg dose vs 21% with 10mg (Goodwin et al., JAMA, 2023)

Agin-Liebes et al., Journal of Psychopharmacology, 2020

View as image ↗

How long psilocybin lasts for depression is the specific question that clinical researchers have been tracking across a growing body of trials, and the answer is now more precise than the generic summaries suggest. Response begins within days, not weeks. Peak effects are measurable at four weeks. Durability at six and twelve months is supported by multiple trials. And in one long-term follow-up study of cancer-related depression and anxiety, a majority of participants maintained significant improvements at the 4.5-year mark. Whether the same duration profile applies across populations and protocols is the honest question the field is still working through.

This article maps the duration evidence as a timeline, study by study, with the specific numbers each trial reported. For the broader clinical evidence picture covering mechanisms and the largest trials, the complete guide to psilocybin for major depression covers those in depth.

The Duration Timeline: What the Clinical Data Shows

The duration question can be answered at four distinct timepoints: days, weeks, months, and years. Each has its own evidence base.

Within the first one to eight days after a psilocybin session, participants in clinical trials typically show measurable improvement on depression rating scales. Goodwin and colleagues, testing a single dose of COMP360 psilocybin in 104 patients with major depressive disorder, found that differences between the 25mg and 10mg groups were already detectable by Day 8 of their assessment.^[2] The 25mg group showed approximately 37% average reduction on the Montgomery-Asberg Depression Rating Scale (MADRS), a structured clinician-rated depression measure, compared to 21% for the 10mg group. That difference opened up quickly rather than gradually.

At four weeks, the evidence is the most robust. Multiple trials use four weeks as their primary endpoint, and the response rates at this timepoint are the headline numbers most commonly cited: 71% responders and 54% in remission in the Davis 2021 Hopkins trial, meaningful MADRS reductions in the Goodwin JAMA 2023 trial, and consistent results across the trials synthesized in the Metaxa 2024 BMJ meta-analysis.^[6]

At six months and twelve months, the picture becomes more variable by individual. Davis 2021 reported that antidepressant effects were maintained in the majority of participants at 12-month follow-up.^[1] "Majority" means more than half maintained benefit, but it also means a meaningful proportion did not. The 2025 long-term observational follow-up of prior trial participants found sustained antidepressant benefit at 12 months and beyond, with benefits in evidence more than a year after the original trial sessions.^[3]

At four-plus years, the data comes from a single follow-up study of the NYU cancer distress trial population, which is a specific and small group, and will be discussed in its own section below.

Why Effects Appear in Days, Not Weeks

The speed of onset is one of the features that most distinguishes psilocybin from conventional antidepressants, and it has a mechanistic explanation.

Standard antidepressants, specifically SSRIs, work primarily by blocking the reuptake of serotonin, increasing the amount available in the synapse. The mood-related benefit from this mechanism takes four to six weeks to develop — a lag researchers attribute partly to the time required for downstream receptor adaptations and neurochemical rebalancing. Patients starting SSRIs are counseled to expect weeks before seeing any effect.

Psilocybin binds directly to serotonin 2A receptors, which sit on specific cell types throughout the brain including neurons in layers four and five of the cortex, and triggers a cascade that includes promotion of new synaptic connections. The brain changes happen during and immediately after the session, not gradually over weeks of daily dosing.

Davis and colleagues' 2021 Hopkins trial reported rapid symptom improvement in the first week, with effects continuing to grow through the four-week assessment point.^[1] The two-session protocol in that trial (one session at week one, a second at week three) produced a 71% response rate at four weeks, with responders defined as those showing at least a 50% reduction from baseline depression scores. That's a response rate substantially above what standard antidepressants show in the same 4-week window.

The Metaxa 2024 meta-analysis, which pooled results from Phase 2 randomized trials, confirmed that psilocybin produces significantly larger reductions in depression scores compared to placebo across these early assessment windows.^[6] The rapid onset is not an artifact of one trial — it's consistent across the evidence base.

The Hopkins MDD Trial: Breaking Down the 4-Week Numbers

The Davis 2021 trial at Johns Hopkins was the first randomized clinical trial of psilocybin-assisted therapy specifically in adults with major depressive disorder, and its four-week numbers remain the most cited in the clinical literature.

Davis and colleagues enrolled 27 adults with diagnosed MDD who had not responded to at least one antidepressant.^[1] Participants received two psilocybin sessions (20mg in the first session, 30mg in the second, approximately three weeks apart) alongside psychotherapy support before, during, and after sessions. The trial used a waitlist control rather than a placebo, which is a design limitation worth noting upfront.

The primary finding: 71% of participants met the criteria for response (at least 50% reduction in depression scores from baseline) and 54% met criteria for remission (depression scores in the normal range) at the four-week primary assessment. These are response rates significantly above what is typically reported for antidepressant medications in treatment-naive populations.

The 12-month follow-up data from the same cohort found that antidepressant effects were maintained in the majority of participants, though some did return to previous depression levels over the year. Davis reported that 58% of participants maintained response status and 54% maintained remission status at 12 months, which are substantial durability numbers from a trial this size.

For those tracking how this compares across trials, the results from the largest clinical trials provides a head-to-head comparison across all the major trial findings.

What Happens Between 3 and 6 Months: The Durability Window

The three-to-six-month period is where the most clinically meaningful durability questions lie, and where the honest picture includes a relapse signal.

Goodwin and colleagues' 2023 JAMA trial of a single dose in 104 MDD patients provides the clearest dose-dependent durability data in this window.^[2] Patients who received 25mg showed substantially better outcomes than those who received 10mg both at the Day 8 assessment and at subsequent follow-up points, establishing that the dose matters not just for initial response but for how long that response lasts.

The meta-analytic picture, as synthesized by Metaxa and colleagues across Phase 2 randomized trials, shows consistent antidepressant effects relative to placebo in these timeframes.^[6] The direction is clear. But the individual patient data tells a more nuanced story: among initial responders, a portion return toward baseline depression levels by six months. This is not unique to psilocybin — conventional antidepressants show similar or higher relapse rates when discontinued — but it's an important framing for anyone interpreting the trial results.

The honest picture at six months is: a majority of trial participants who responded at four weeks maintain that response at six months, and some of those maintain it through twelve months. A meaningful minority do not. The factors that predict who maintains benefit versus who relapses are still being studied, and who responds best to psilocybin for depression covers the predictor evidence in detail.

The Long-Term Data: What 12 Months and Beyond Actually Shows

Two bodies of evidence address the longest timescales: a 2025 observational follow-up of prior trial participants, and a 4.5-year follow-up of the NYU cancer distress population.

The 2025 long-term observational follow-up study tracked participants from earlier psilocybin trials through twelve months and beyond.^[3] The finding: antidepressant benefits were sustained in a meaningful proportion of participants at 12-plus months from their original sessions. This is observational data, not a controlled trial, but it follows a trial population, which gives it more grounding than uncontrolled case series. The study confirms that single-dose antidepressant effects are not purely transient — for some participants, the benefit persists well past the year mark.

The Agin-Liebes 2020 follow-up study is the longest duration data in the literature. It tracked 16 participants from the NYU psilocybin for cancer-related distress trial out to 4.5 years after treatment.^[5] The population is important context: these were cancer patients dealing with life-threatening illness-related depression and anxiety, not general population major depressive disorder. At 4.5-year follow-up, 60-80% of participants maintained significant reductions in depression and anxiety compared to their pre-treatment baseline. Depression rates remained below pre-study baseline for the majority of participants across the follow-up period.

Two caveats matter for interpreting this result: the sample size is 16 people, which is small enough that individual variation carries substantial weight; and the population (cancer-related distress) may differ in important ways from general MDD. But for the question of whether psilocybin effects can last years rather than months, this is the only controlled follow-up data available, and the answer it gives is yes, at least in this population and with this protocol. For a detailed treatment of the 6-month and 12-month data across multiple trials, the psilocybin depression 6-month and 12-month follow-up data examines those results specifically.

When One Dose Isn't Enough: What the Repeat-Dose Evidence Shows

Most clinical trials use either one or two psilocybin sessions as the treatment protocol. The question of whether more sessions produce longer-lasting results was addressed directly by Rosenblat and colleagues in 2024.

Rosenblat and colleagues tested a repeated-dose protocol, specifically two sessions rather than one, in patients with treatment-resistant depression (TRD), a population that has failed to respond to multiple prior antidepressant medications.^[4] The trial found that the two-session protocol produced sustained antidepressant response, supporting the standard two-session design used in the majority of larger trials including Davis 2021.

The two-session structure matters for duration. Davis and colleagues' Hopkins protocol used sessions approximately three weeks apart, and the combination of sessions appeared to extend and deepen the initial response that would follow a single session alone.^[1] The 71% response rate at four weeks in that trial reflects a two-session result, not a single-dose result. The Goodwin 2023 JAMA trial, which tested a single dose, reported a 37% MADRS reduction at the same timepoint.^[2] The difference in those numbers suggests the second session contributes meaningfully to outcome, not just to duration.

For patients who experience initial response followed by gradual return of symptoms, the repeat-dose data suggests a second session represents a viable clinical approach rather than a failed treatment. Whether a third session would produce further extension of benefit is not yet well-characterized in the published data.

The Bottom Line

Psilocybin produces antidepressant effects that begin within days of a session, with most clinical trials using four weeks as their primary endpoint and reporting response rates of 54-71% in that window. The duration extends to twelve months in the majority of initial responders, based on the Davis 2021 Hopkins trial and a 2025 long-term follow-up study. The Agin-Liebes 2020 follow-up of the NYU cancer distress population documents maintained improvements at 4.5 years in 60-80% of participants, though the small sample and specific population limit how broadly that result generalizes. Two-session protocols consistently produce better outcomes than single-dose protocols in direct comparisons.

Frequently Asked Questions

How long does psilocybin therapy last for depression?

In clinical trials, antidepressant effects begin within one to eight days and are measurable at four weeks in 54-71% of participants. At twelve months, the majority of initial responders in the Davis 2021 Hopkins trial had maintained their response. A 2025 long-term observational follow-up found sustained benefits beyond twelve months in a meaningful proportion of participants from prior trials. The 4.5-year follow-up by Agin-Liebes and colleagues found 60-80% maintained improvement, though that study involved cancer patients specifically. Effects are not permanent for everyone, and a portion of initial responders see symptoms return by six months.

Is psilocybin a one-time treatment for depression?

Most clinical trials use two sessions rather than one, and the two-session protocols consistently outperform single-session protocols in direct comparisons. Davis et al.'s 2021 Hopkins trial used two sessions (20mg then 30mg, three weeks apart) and found 71% response at four weeks. Goodwin et al.'s 2023 single-dose JAMA trial found approximately 37% MADRS reduction at the same timepoint. Rosenblat and colleagues demonstrated in a 2024 RCT that repeated-dose protocols produce sustained antidepressant response in treatment-resistant patients, supporting the two-session standard. Some participants who initially respond later return to baseline and may benefit from additional sessions.

Do the effects of psilocybin wear off for depression?

For a proportion of participants, yes. The Davis 2021 Hopkins trial reported that while a majority maintained response at twelve months, not all initial responders were still in remission at that point. The Metaxa 2024 BMJ meta-analysis confirmed significant antidepressant effects relative to placebo but also reflects a range of individual outcomes. The longer-duration data, including the 2025 observational follow-up and the Agin-Liebes 4.5-year follow-up, shows that effects can persist years in some individuals, particularly those who had strong initial responses. Whether effects wear off appears to depend on the initial response quality, session protocol, and individual factors that researchers are still characterizing.

How many sessions of psilocybin therapy do you need for depression?

Two sessions is the standard protocol in most clinical trials, and two-session results consistently exceed single-dose results. The Hopkins MDD trial by Davis et al. used two sessions and reported 71% response at four weeks. The Goodwin 2023 single-dose trial reported approximately 37% MADRS reduction. Rosenblat et al.'s 2024 RCT tested repeated doses specifically and found that a two-session protocol produced sustained antidepressant response in treatment-resistant patients. Most current clinical trial protocols and emerging clinical protocols follow a two-session structure with psychotherapy support.

Can one dose of psilocybin cure depression?

Clinical trials do not use the word "cure," and the duration data makes clear why. A single 25mg dose in Goodwin et al.'s 2023 JAMA trial produced approximately 37% reduction on the MADRS depression scale, a meaningful clinical improvement, but effects were variable over follow-up. The Metaxa 2024 BMJ meta-analysis confirmed that psilocybin significantly reduces depression symptoms versus placebo across trials, but also reflects a distribution of individual outcomes. Some participants maintain large gains for a year or more. Others see effects diminish by six months. "Significant sustained improvement for many participants" is more accurate than "cure," and more accurate than "temporary relief" for the fraction with lasting outcomes.

Do you need to repeat psilocybin treatment?

Whether additional sessions are needed depends on individual response. The clinical trial baseline is two sessions, as used in Davis et al. 2021, based on evidence that two-session protocols outperform single-session. For patients who respond strongly and maintain that response, additional sessions may not be warranted. For patients who experience initial response followed by symptom return, the Rosenblat 2024 RCT of repeated-dose protocols in treatment-resistant patients demonstrated that additional sessions can produce sustained antidepressant response. The 2025 observational follow-up data suggests some patients maintain benefit for 12+ months without additional sessions, making individual outcome trajectory the primary guide.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.